 | • レポートコード：GIR-2104Z09102 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、104ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥487,200 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥730,800 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥974,400 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、髄膜炎菌性疾患治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。髄膜炎菌性疾患治療の種類別市場規模（抗生物質、ワクチン）、用途別市場規模（病院、ドラッグストア、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・髄膜炎菌性疾患治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、GlaxoSmithKline、Sanofi Pasteur、Novartis ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：抗生物質、ワクチン ・用途別分析2016年-2026年：病院、ドラッグストア、その他 ・髄膜炎菌性疾患治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・髄膜炎菌性疾患治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・髄膜炎菌性疾患治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・髄膜炎菌性疾患治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・髄膜炎菌性疾患治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Meningococcal Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Meningococcal Disease Treatment size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Meningococcal Disease Treatment market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Meningococcal Disease Treatment market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Antibiotics
Vaccines
Market segment by Application, can be divided into
Hospitals
Drugstores
Others
Market segment by players, this report covers
Pfizer
GlaxoSmithKline
Sanofi Pasteur
Novartis
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Meningococcal Disease Treatment
1.2 Classification of Meningococcal Disease Treatment by Type
1.2.1 Overview: Global Meningococcal Disease Treatment Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Meningococcal Disease Treatment Revenue Market Share by Type in 2020
1.2.3 Antibiotics
1.2.4 Vaccines
1.3 Global Meningococcal Disease Treatment Market by Application
1.3.1 Overview: Global Meningococcal Disease Treatment Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Meningococcal Disease Treatment Market Size & Forecast
1.5 Global Meningococcal Disease Treatment Market Size and Forecast by Region
1.5.1 Global Meningococcal Disease Treatment Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Meningococcal Disease Treatment Market Size by Region, (2016-2021)
1.5.3 North America Meningococcal Disease Treatment Market Size and Prospect (2016-2026)
1.5.4 Europe Meningococcal Disease Treatment Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Meningococcal Disease Treatment Market Size and Prospect (2016-2026)
1.5.6 South America Meningococcal Disease Treatment Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Meningococcal Disease Treatment Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Meningococcal Disease Treatment Market Drivers
1.6.2 Meningococcal Disease Treatment Market Restraints
1.6.3 Meningococcal Disease Treatment Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Meningococcal Disease Treatment Product and Solutions
2.1.4 Pfizer Meningococcal Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business
2.2.3 GlaxoSmithKline Meningococcal Disease Treatment Product and Solutions
2.2.4 GlaxoSmithKline Meningococcal Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 GlaxoSmithKline Recent Developments and Future Plans
2.3 Sanofi Pasteur
2.3.1 Sanofi Pasteur Details
2.3.2 Sanofi Pasteur Major Business
2.3.3 Sanofi Pasteur Meningococcal Disease Treatment Product and Solutions
2.3.4 Sanofi Pasteur Meningococcal Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Sanofi Pasteur Recent Developments and Future Plans
2.4 Novartis
2.4.1 Novartis Details
2.4.2 Novartis Major Business
2.4.3 Novartis Meningococcal Disease Treatment Product and Solutions
2.4.4 Novartis Meningococcal Disease Treatment Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Novartis Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Meningococcal Disease Treatment Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Meningococcal Disease Treatment Players Market Share
3.2.2 Top 10 Meningococcal Disease Treatment Players Market Share
3.2.3 Market Competition Trend
3.3 Meningococcal Disease Treatment Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Meningococcal Disease Treatment Revenue and Market Share by Type (2016-2021)
4.2 Global Meningococcal Disease Treatment Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Meningococcal Disease Treatment Revenue Market Share by Application (2016-2021)
5.2 Meningococcal Disease Treatment Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Meningococcal Disease Treatment Revenue by Type (2016-2026)
6.2 North America Meningococcal Disease Treatment Revenue by Application (2016-2026)
6.3 North America Meningococcal Disease Treatment Market Size by Country
6.3.1 North America Meningococcal Disease Treatment Revenue by Country (2016-2026)
6.3.2 United States Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
6.3.3 Canada Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
6.3.4 Mexico Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Meningococcal Disease Treatment Revenue by Type (2016-2026)
7.2 Europe Meningococcal Disease Treatment Revenue by Application (2016-2026)
7.3 Europe Meningococcal Disease Treatment Market Size by Country
7.3.1 Europe Meningococcal Disease Treatment Revenue by Country (2016-2026)
7.3.2 Germany Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
7.3.3 France Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
7.3.5 Russia Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
7.3.6 Italy Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Meningococcal Disease Treatment Revenue by Type (2016-2026)
8.2 Asia-Pacific Meningococcal Disease Treatment Revenue by Application (2016-2026)
8.3 Asia-Pacific Meningococcal Disease Treatment Market Size by Region
8.3.1 Asia-Pacific Meningococcal Disease Treatment Revenue by Region (2016-2026)
8.3.2 China Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
8.3.3 Japan Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
8.3.4 South Korea Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
8.3.5 India Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
8.3.7 Australia Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Meningococcal Disease Treatment Revenue by Type (2016-2026)
9.2 South America Meningococcal Disease Treatment Revenue by Application (2016-2026)
9.3 South America Meningococcal Disease Treatment Market Size by Country
9.3.1 South America Meningococcal Disease Treatment Revenue by Country (2016-2026)
9.3.2 Brazil Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
9.3.3 Argentina Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Meningococcal Disease Treatment Revenue by Type (2016-2026)
10.2 Middle East & Africa Meningococcal Disease Treatment Revenue by Application (2016-2026)
10.3 Middle East & Africa Meningococcal Disease Treatment Market Size by Country
10.3.1 Middle East & Africa Meningococcal Disease Treatment Revenue by Country (2016-2026)
10.3.2 Turkey Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
10.3.4 UAE Meningococcal Disease Treatment Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Meningococcal Disease Treatment Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Meningococcal Disease Treatment Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Meningococcal Disease Treatment Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Meningococcal Disease Treatment Revenue (USD Million) by Region (2016-2021)
Table 5. Global Meningococcal Disease Treatment Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Meningococcal Disease Treatment Product and Solutions
Table 9. Pfizer Meningococcal Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 11. GlaxoSmithKline Major Business
Table 12. GlaxoSmithKline Meningococcal Disease Treatment Product and Solutions
Table 13. GlaxoSmithKline Meningococcal Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Sanofi Pasteur Corporate Information, Head Office, and Major Competitors
Table 15. Sanofi Pasteur Major Business
Table 16. Sanofi Pasteur Meningococcal Disease Treatment Product and Solutions
Table 17. Sanofi Pasteur Meningococcal Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Novartis Corporate Information, Head Office, and Major Competitors
Table 19. Novartis Major Business
Table 20. Novartis Meningococcal Disease Treatment Product and Solutions
Table 21. Novartis Meningococcal Disease Treatment Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Global Meningococcal Disease Treatment Revenue (USD Million) by Players (2019-2021)
Table 23. Global Meningococcal Disease Treatment Revenue Share by Players (2019-2021)
Table 24. Breakdown of Meningococcal Disease Treatment by Company Type (Tier 1, Tier 2 and Tier 3)
Table 25. Meningococcal Disease Treatment Players Head Office, Products and Services Provided
Table 26. Meningococcal Disease Treatment Mergers & Acquisitions in the Past Five Years
Table 27. Meningococcal Disease Treatment New Entrants and Expansion Plans
Table 28. Global Meningococcal Disease Treatment Revenue (USD Million) by Type (2016-2021)
Table 29. Global Meningococcal Disease Treatment Revenue Share by Type (2016-2021)
Table 30. Global Meningococcal Disease Treatment Revenue Forecast by Type (2021-2026)
Table 31. Global Meningococcal Disease Treatment Revenue by Application (2016-2021)
Table 32. Global Meningococcal Disease Treatment Revenue Forecast by Application (2021-2026)
Table 33. North America Meningococcal Disease Treatment Revenue by Type (2016-2021) & (USD Million)
Table 34. North America Meningococcal Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 35. North America Meningococcal Disease Treatment Revenue by Application (2016-2021) & (USD Million)
Table 36. North America Meningococcal Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 37. North America Meningococcal Disease Treatment Revenue by Country (2016-2021) & (USD Million)
Table 38. North America Meningococcal Disease Treatment Revenue by Country (2021-2026) & (USD Million)
Table 39. Europe Meningococcal Disease Treatment Revenue by Type (2016-2021) & (USD Million)
Table 40. Europe Meningococcal Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 41. Europe Meningococcal Disease Treatment Revenue by Application (2016-2021) & (USD Million)
Table 42. Europe Meningococcal Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 43. Europe Meningococcal Disease Treatment Revenue by Country (2016-2021) & (USD Million)
Table 44. Europe Meningococcal Disease Treatment Revenue by Country (2021-2026) & (USD Million)
Table 45. Asia-Pacific Meningococcal Disease Treatment Revenue by Type (2016-2021) & (USD Million)
Table 46. Asia-Pacific Meningococcal Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 47. Asia-Pacific Meningococcal Disease Treatment Revenue by Application (2016-2021) & (USD Million)
Table 48. Asia-Pacific Meningococcal Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 49. Asia-Pacific Meningococcal Disease Treatment Revenue by Region (2016-2021) & (USD Million)
Table 50. Asia-Pacific Meningococcal Disease Treatment Revenue by Region (2021-2026) & (USD Million)
Table 51. South America Meningococcal Disease Treatment Revenue by Type (2016-2021) & (USD Million)
Table 52. South America Meningococcal Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 53. South America Meningococcal Disease Treatment Revenue by Application (2016-2021) & (USD Million)
Table 54. South America Meningococcal Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 55. South America Meningococcal Disease Treatment Revenue by Country (2016-2021) & (USD Million)
Table 56. South America Meningococcal Disease Treatment Revenue by Country (2021-2026) & (USD Million)
Table 57. Middle East & Africa Meningococcal Disease Treatment Revenue by Type (2016-2021) & (USD Million)
Table 58. Middle East & Africa Meningococcal Disease Treatment Revenue by Type (2021-2026) & (USD Million)
Table 59. Middle East & Africa Meningococcal Disease Treatment Revenue by Application (2016-2021) & (USD Million)
Table 60. Middle East & Africa Meningococcal Disease Treatment Revenue by Application (2021-2026) & (USD Million)
Table 61. Middle East & Africa Meningococcal Disease Treatment Revenue by Country (2016-2021) & (USD Million)
Table 62. Middle East & Africa Meningococcal Disease Treatment Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Meningococcal Disease Treatment Picture
Figure 2. Global Meningococcal Disease Treatment Revenue Market Share by Type in 2020
Figure 3. Antibiotics
Figure 4. Vaccines
Figure 5. Meningococcal Disease Treatment Revenue Market Share by Application in 2020
Figure 6. Hospitals Picture
Figure 7. Drugstores Picture
Figure 8. Others Picture
Figure 9. Global Meningococcal Disease Treatment Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Meningococcal Disease Treatment Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Meningococcal Disease Treatment Revenue Market Share by Region (2016-2026)
Figure 12. Global Meningococcal Disease Treatment Revenue Market Share by Region in 2020
Figure 13. North America Meningococcal Disease Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Meningococcal Disease Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Meningococcal Disease Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Meningococcal Disease Treatment Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Meningococcal Disease Treatment Market Drivers
Figure 18. Meningococcal Disease Treatment Market Restraints
Figure 19. Meningococcal Disease Treatment Market Trends
Figure 20. Pfizer Recent Developments and Future Plans
Figure 21. GlaxoSmithKline Recent Developments and Future Plans
Figure 22. Sanofi Pasteur Recent Developments and Future Plans
Figure 23. Novartis Recent Developments and Future Plans
Figure 25. Global Meningococcal Disease Treatment Revenue Share by Players in 2020
Figure 26. Meningococcal Disease Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 27. Global Top 3 Players Meningococcal Disease Treatment Revenue Market Share in 2020
Figure 28. Global Top 10 Players Meningococcal Disease Treatment Revenue Market Share in 2020
Figure 29. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 30. Global Meningococcal Disease Treatment Revenue Share by Type in 2020
Figure 31. Global Meningococcal Disease Treatment Market Share Forecast by Type (2021-2026)
Figure 32. Global Meningococcal Disease Treatment Revenue Share by Application in 2020
Figure 33. Global Meningococcal Disease Treatment Market Share Forecast by Application (2021-2026)
Figure 34. North America Meningococcal Disease Treatment Sales Market Share by Type (2016-2026)
Figure 35. North America Meningococcal Disease Treatment Sales Market Share by Application (2016-2026)
Figure 36. North America Meningococcal Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 37. United States Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 38. Canada Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 39. Mexico Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 40. Europe Meningococcal Disease Treatment Sales Market Share by Type (2016-2026)
Figure 41. Europe Meningococcal Disease Treatment Sales Market Share by Application (2016-2026)
Figure 42. Europe Meningococcal Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 43. Germany Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. France Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. United Kingdom Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. Russia Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Italy Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Asia-Pacific Meningococcal Disease Treatment Sales Market Share by Type (2016-2026)
Figure 49. Asia-Pacific Meningococcal Disease Treatment Sales Market Share by Application (2016-2026)
Figure 50. Asia-Pacific Meningococcal Disease Treatment Revenue Market Share by Region (2016-2026)
Figure 51. China Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Japan Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. South Korea Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. India Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. Southeast Asia Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Australia Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. South America Meningococcal Disease Treatment Sales Market Share by Type (2016-2026)
Figure 58. South America Meningococcal Disease Treatment Sales Market Share by Application (2016-2026)
Figure 59. South America Meningococcal Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 60. Brazil Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. Argentina Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Middle East and Africa Meningococcal Disease Treatment Sales Market Share by Type (2016-2026)
Figure 63. Middle East and Africa Meningococcal Disease Treatment Sales Market Share by Application (2016-2026)
Figure 64. Middle East and Africa Meningococcal Disease Treatment Revenue Market Share by Country (2016-2026)
Figure 65. Turkey Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Saudi Arabia Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. UAE Meningococcal Disease Treatment Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. Methodology
Figure 69. Research Process and Data Source
世界の髄膜炎菌性疾患治療市場規模・現状・予測（2021年-2027年） Meningococcal disease is a severe infection of meninges, the thin layers of tissue covering brain and spinal cord, caused by the bacteria Neisseria meningitidis. This bacteria can also cause bloodstream infections (septicemia). Bacterial meningitis is severe because of rapid onset and a significant …- 世界の髄膜炎菌性疾患治療薬市場 2021：企業別、地域別、種類・用途別 The Meningococcal Disease Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade reg…
- 世界の菌結合型髄膜炎市場規模・現状・予測（2021年-2027年） Meningococcal disease can become life threatening quickly, and teens are at higher risk of getting it. It's a leading cause of bacterial meningitis in teens. Meningitis is a dangerous inflammation of the lining of the brain and spinal cord. Two meningitis vaccines protects against four types of meni…
- 世界のクラッベ病治療市場規模・現状・予測（2021年-2027年） Krabbe disease (KD) (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessi…
- 世界のフォンウィルブランド病治療市場 2021：企業別、地域別、種類・用途別 The Von Willebrand Disease Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…